Latest news with #JacobThaysen
Yahoo
3 days ago
- Business
- Yahoo
ILMN Q1 Earnings Call: Clinical Growth and Cost Actions Offset Research and China Headwinds
Genomics company Illumina (NASDAQ:ILMN) reported Q1 CY2025 results beating Wall Street's revenue expectations , but sales fell by 1.4% year on year to $1.04 billion. Its non-GAAP profit of $0.97 per share was 3.2% above analysts' consensus estimates. Is now the time to buy ILMN? Find out in our full research report (it's free). Revenue: $1.04 billion vs analyst estimates of $1.04 billion (1.4% year-on-year decline, 0.5% beat) Adjusted EPS: $0.97 vs analyst estimates of $0.94 (3.2% beat) Adjusted EBITDA: $272.6 million vs analyst estimates of $258.3 million (26.2% margin, 5.5% beat) Management lowered its full-year Adjusted EPS guidance to $4.25 at the midpoint, a 7.1% decrease Operating Margin: 15.8%, up from 11% in the same quarter last year Organic Revenue fell 1.2% year on year, in line with the same quarter last year Market Capitalization: $13.45 billion Illumina's first quarter results reflected the resilience of its clinical sequencing business and ongoing adoption of its NovaSeq X platform. Management highlighted continued momentum in clinical instrument placements, with CEO Jacob Thaysen noting, 'NovaSeq X instruments continue to perform well, exceeding our expectations with another quarter of over 60 placements in Q1.' While research and academic customers showed more conservative purchasing behavior due to U.S. funding uncertainty, Thaysen attributed the company's performance to operational execution and a stable base of high-throughput consumable usage. CFO Ankur Dhingra added that early year ordering activity—particularly long-range purchase commitments—was stronger than in prior years, providing a measure of stability despite broader macroeconomic challenges. Illumina's ability to maintain operational execution and product adoption under challenging market conditions was a key theme throughout the call. Looking forward, management's outlook for the year is shaped by several headwinds, including new export restrictions to China, a constrained research funding environment, and incremental tariffs on imported products. Thaysen acknowledged that these factors have led to a downward revision of full-year earnings guidance, stating, 'We are revising our guidance to reflect both the headwinds and the proactive steps we are taking to protect earnings.' The team emphasized ongoing cost reductions, supply chain optimization, and targeted pricing actions as central to mitigating these pressures. Dhingra explained that the company expects to offset about half of the tariff impact in 2025 and sees stronger growth opportunities in clinical markets and new product launches as key to future performance. Management remains focused on advancing its innovation pipeline, particularly in multi-omics, while closely monitoring evolving regulatory and funding developments. Management attributed the quarter's results to continued clinical market strength, the successful transition to NovaSeq X, and proactive cost controls, while addressing challenges in China and U.S. research funding. Clinical placements drive growth: Illumina's clinical segment continued to show robust demand, with more than 60 NovaSeq X instruments placed in Q1. This transition is progressing especially well among clinical customers, which management sees as a key lever for volume-driven revenue growth as clinical sequencing expands. Research funding pressures: The company noted that research and academic customers became more conservative with consumables purchases in Q1, driven by uncertainty around U.S. government research funding. This softness was most pronounced in the mid-throughput segment, which is more sensitive to delayed instrument purchases and lower utilization. China export restrictions: Recent export controls have limited Illumina's ability to ship sequencing instruments to China, resulting in a significant reduction in projected revenue from the region. Management will now provide separate guidance for Greater China to clarify the underlying performance of the rest of the business. Tariff impact and mitigation: New U.S. import tariffs on goods from Singapore and certain other countries are expected to increase Illumina's costs. The company is actively working to offset these through supply chain changes and selective price increases, though only partial mitigation is anticipated in 2025. Cost reduction initiatives: Illumina implemented a $100 million global cost reduction program in March, which is expected to result in flat or slightly down operating expenses for the rest of the year. Management believes these measures, combined with operational discipline, will help protect margins amid ongoing revenue headwinds. Looking ahead, Illumina's guidance is shaped by geopolitical headwinds, funding constraints, and ongoing cost management, with clinical market expansion and innovation serving as primary growth drivers. Clinical market momentum: Management expects continued strength in clinical sequencing to partially offset declines in research-driven revenue. Expanded adoption of newer platforms like NovaSeq X within clinical settings is anticipated to drive higher consumable usage and more predictable revenue streams. Tariff and supply chain adjustments: The company is implementing supply chain optimizations and targeted pricing actions to address increased costs from tariffs. Management stated that about half of the tariff impact will be mitigated in 2025, with further actions expected to improve the cost structure in 2026. Ongoing innovation pipeline: Illumina highlighted upcoming product launches—including a new single-cell CRISPR research tool and early access proteomics solution—as key to supporting long-term growth. These innovations are designed to expand the multi-omics ecosystem and open new market opportunities, despite near-term market uncertainties. In the quarters ahead, our analysts will watch (1) the pace of NovaSeq X adoption and its effect on clinical consumable volumes, (2) the company's ability to mitigate tariff-related cost increases through supply chain and pricing actions, and (3) the impact of ongoing cost reduction initiatives on operating margins. Key product launches and developments in the regulatory environment for China and research funding will also be important signposts. Illumina currently trades at a forward P/E ratio of 18.4×. At this valuation, is it a buy or sell post earnings? The answer lies in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics
SAN DIEGO, June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social Responsibility (CSR) Report. The report spotlights the ways Illumina is making precision health more accessible than ever before, and its ongoing work to empower people and communities, embed sustainability across its business, operate responsibly, and lead with integrity. "At Illumina, we work relentlessly in our mission to improve human health by unlocking the power of the genome, and our CSR strategy is an essential part of that," said Jacob Thaysen, CEO of Illumina. "Our innovation has driven incredible breakthroughs—but those breakthroughs only matter if they can be accessed. Our CSR efforts are designed to drive greater access to genomics technologies and improve health equity for billions of people around the world. We continue to take meaningful steps to champion patients, communities, employees, and the planet as we work to create a healthier and more sustainable future." 2024 highlights Making genomics affordable and accessible: Integrating genomics across the care continuum is critical to positive health outcomes, but gaps in health insurance coverage continue to put genomic testing out of reach for many. In 2024, Illumina's advocacy efforts supported the expansion of health care coverage for genomic testing to an additional 100 million people compared to 2023, resulting in a total of 1.4 billion lives covered. Significantly reducing packaging and increasing product sustainability efforts: In 2024, Illumina achieved an 80% reduction in packaging since 2019, surpassing its 2030 target of a 75% reduction. The MiSeq i100 Series, launched in 2024 and designed with sustainability in mind, also achieved a 35% reduction in climate change impact, thanks to its reduced packaging and the room-temperature shipping and storage of its reagents. Operating sustainably: 100% of Illumina's global electricity consumption came from renewable sources for the third consecutive year. Impact areas Illumina's CSR program is rooted in four key areas, and the company's CSR report demonstrates progress made in 2024 in each: Accelerating access to genomics Illumina launched the MiSeq i100 Series, benchtop sequencers designed for faster run times and simplified setup and analysis. Illumina invested in the future of genomics by expanding access to STEM education. The company has reached 2.1 million STEM learners since 2019 through direct programming, nonprofit partners, and employee engagement. Nurturing our people and communities Fifty-two percent of Illumina's employees participated in giving and volunteering programs, donating 91,370 volunteer hours. Illumina maintained a zero net pay gap for the sixth consecutive year. Integrating sustainability Illumina realized a 45% decrease in scopes 1 and 2 emissions from its 2019 baseline. Five Illumina labs completed the eight-month certification process with My Green Lab, the gold standard for laboratory sustainability best practices around the world. Operating responsibly 100% of Illumina's core facilities participated in third-party audit programs. Illumina was named for the sixth year in a row to the Dow Jones Best-in-Class World Index and the Dow Jones Best-in-Class North America Index (formerly part of the Dow Jones Sustainability Indices) and received a top industry ISS Corporate Governance rating. Illumina continued to exercise strong corporate governance with an independent Board of Directors (all independent with the exception of the CEO) and an independent Board Chair. The full report is available on Illumina's CSR website. About IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube. Contacts Investors:Brian Blanchett+1.858.291.6421ir@ Media:Christine Douglasspr@ View original content to download multimedia: SOURCE Illumina, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18-04-2025
- Business
- Yahoo
Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let's take a look at how Illumina (NASDAQ:ILMN) and the rest of the life sciences tools & services stocks fared in Q4. The life sciences tools and services sector supports the research, development, and commercialization of biotechnology and pharmaceutical products. These companies offer a broad range of tools, from lab consumables and testing equipment to data analytics platforms and clinical trial support. There is recurring revenue potential from long-term contracts, high margins from specialized products, and the growing demand for precision medicine and data-driven insights. However, challenges include dependence on research and development budgets from large pharmaceutical companies and the boom and bust nature of smaller biotech companies. Looking forward, the life sciences tools and services sector is expected to benefit from strong tailwinds, including advancements in genomics and the rising focus on personalized medicine. Ongoing adoption of artificial intelligence in research and drug discovery, along with the growing need for regulatory compliance and data analytics, should provide longer-term demand support. However, headwinds such as the uncertainty around healthcare and research funding as well as pricing pressures from cost-conscious customers may feed into uncertainty in the sector. The 21 life sciences tools & services stocks we track reported a mixed Q4. As a group, revenues beat analysts' consensus estimates by 1.1% while next quarter's revenue guidance was in line. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 29.1% since the latest earnings results. Pioneering the ability to read the human genome at unprecedented speed and affordability, Illumina (NASDAQ:ILMN) develops and sells advanced DNA sequencing and microarray technologies that allow researchers and clinicians to analyze genetic variations and functions. Illumina reported revenues of $1.10 billion, flat year on year. This print exceeded analysts' expectations by 2.1%. Overall, it was a strong quarter for the company with a solid beat of analysts' full-year EPS guidance estimates. "The Illumina team delivered fourth quarter revenue that exceeded our expectations, and we made significant progress in 2024 toward our goals to drive customer-centric innovation, margin expansion, and EPS growth," said Jacob Thaysen, Chief Executive Officer. The stock is down 41% since reporting and currently trades at $72.40. Is now the time to buy Illumina? Access our full analysis of the earnings results here, it's free. With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ:TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development. Bio-Techne reported revenues of $297 million, up 9% year on year, outperforming analysts' expectations by 4.2%. The business had an exceptional quarter with a solid beat of analysts' organic revenue estimates and a decent beat of analysts' EPS estimates. Bio-Techne delivered the biggest analyst estimates beat among its peers. The stock is down 31.8% since reporting. It currently trades at $49.52. Is now the time to buy Bio-Techne? Access our full analysis of the earnings results here, it's free. Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ:PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness. PacBio reported revenues of $39.22 million, down 32.8% year on year, falling short of analysts' expectations by 1.8%. It was a disappointing quarter as it posted a miss of analysts' EPS estimates. PacBio delivered the weakest performance against analyst estimates and slowest revenue growth in the group. As expected, the stock is down 20.4% since the results and currently trades at $1.17. Read our full analysis of PacBio's results here. Born from a real estate investment trust that transformed into a manufacturing powerhouse, Danaher (NYSE:DHR) is a global science and technology company that provides specialized equipment, software, and services for biotechnology, life sciences, and diagnostics. Danaher reported revenues of $6.54 billion, up 2.1% year on year. This number surpassed analysts' expectations by 1.6%. Overall, it was a strong quarter as it also put up an impressive beat of analysts' organic revenue estimates. The stock is down 24.2% since reporting and currently trades at $187.84. Read our full, actionable report on Danaher here, it's free. With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels. Bruker reported revenues of $979.6 million, up 14.6% year on year. This print beat analysts' expectations by 1.4%. Zooming out, it was a mixed quarter as it also logged a solid beat of analysts' organic revenue estimates. The stock is down 29.8% since reporting and currently trades at $36.28. Read our full, actionable report on Bruker here, it's free. Thanks to the Fed's rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn't send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump's November win lit a fire under major indices and sent them to all-time highs. However, there's still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy. Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Sign in to access your portfolio
Yahoo
19-02-2025
- Business
- Yahoo
Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference
SAN DIEGO, Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor session at the AGBT conference. The investor fireside chat will begin at 8:00am Pacific Time (11:00am Eastern Time) on Tuesday, February 25, 2025 and will feature Jacob Thaysen (Chief Executive Officer), Ankur Dhingra (Chief Financial Officer), and Steve Barnard (Chief Technology Officer). Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link – ( To ensure timely connection, please join at least ten minutes before the scheduled start of the session. A replay will be posted on Illumina's website after the event and will be available for at least 30 days following. About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube. Investors: Salli Schwartz +1.858.291.6421 ir@ Media:Bonny Fowler+1.740.641.5579pr@ View original content: SOURCE Illumina, Inc.
Yahoo
07-02-2025
- Business
- Yahoo
Illumina (NASDAQ:ILMN) Beats Q4 Sales Targets
Genomics company Illumina (NASDAQ:ILMN) reported Q4 CY2024 results exceeding the market's revenue expectations , but sales were flat year on year at $1.1 billion. On the other hand, the company's full-year revenue guidance of $4.34 billion at the midpoint came in 1.2% below analysts' estimates. Its non-GAAP profit of $0.86 per share was 6.9% below analysts' consensus estimates. Is now the time to buy Illumina? Find out in our full research report. Revenue: $1.1 billion vs analyst estimates of $1.08 billion (flat year on year, 2.1% beat) Adjusted EPS: $0.86 vs analyst expectations of $0.92 (6.9% miss) Adjusted Operating Income: $218 million vs analyst estimates of $218.1 million (19.7% margin, in line) Management's revenue guidance for the upcoming financial year 2025 is $4.34 billion at the midpoint, missing analyst estimates by 1.2% and implying 0.2% growth (vs -2.3% in FY2024) Adjusted EPS guidance for the upcoming financial year 2025 is $4.58 at the midpoint, beating analyst estimates by 2.7% Operating Margin: 15.9%, up from -14.9% in the same quarter last year Free Cash Flow Margin: 29.2%, up from 15.8% in the same quarter last year Organic Revenue rose 1% year on year (2.5% in the same quarter last year) Market Capitalization: $19.77 billion "The Illumina team delivered fourth quarter revenue that exceeded our expectations, and we made significant progress in 2024 toward our goals to drive customer-centric innovation, margin expansion, and EPS growth," said Jacob Thaysen, Chief Executive Officer. Founded in 1998, Illumina (NASDAQ:ILMN) is a provider of genomic sequencing and analysis technologies for applications in research, clinical diagnostics, and life sciences. Genomics and sequencing companies within the life sciences industry provide the technology for increasingly personalized medicine, drug discovery, and disease research. These firms leverage cutting-edge platforms for high-throughput sequencing and genomic analysis, enabling researchers and healthcare providers to better understand genetic underpinnings of diseases. While the industry enjoys high barriers to entry due to proprietary technology and intellectual property, the business model also faces significant R&D costs, reliance on continued innovation, and exposure to shifts in academic, biotech, and clinical research funding. Over the next few years, the subsector is well-positioned to benefit from tailwinds such as increasing adoption of precision medicine, expanded applications for sequencing technologies in areas like oncology and rare disease diagnostics, and growing use of genomic data in drug development. Advances in artificial intelligence could further enhance the speed and accuracy of genomic insights. However, potential headwinds include price sensitivity among research institutions and healthcare systems that are constantly trying to contain and lower costs. Additionally, regulations around data privacy and genomic testing are not yet set in stone, adding uncertainty to the industry. Examining a company's long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Unfortunately, Illumina's 4.1% annualized revenue growth over the last five years was mediocre. This was below our standard for the healthcare sector and is a poor baseline for our analysis. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Illumina's history shows it grew in the past but relinquished its gains over the last two years, as its revenue fell by 2.4% annually. We can better understand the company's sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don't accurately reflect its fundamentals. Over the last two years, Illumina's organic revenue averaged 1.9% year-on-year declines. Because this number aligns with its normal revenue growth, we can see the company's core operations (not acquisitions and divestitures) drove most of its results. This quarter, Illumina's $1.1 billion of revenue was flat year on year but beat Wall Street's estimates by 2.1%. Looking ahead, sell-side analysts expect revenue to grow 2.4% over the next 12 months. While this projection suggests its newer products and services will catalyze better top-line performance, it is still below average for the sector. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits. Illumina has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average adjusted operating margin of 22.7%. Analyzing the trend in its profitability, Illumina's adjusted operating margin decreased by 2.1 percentage points over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 2.5 percentage points. This performance was poor no matter how you look at it - it shows operating expenses were rising and it couldn't pass those costs onto its customers. This quarter, Illumina generated an adjusted operating profit margin of 19.7%, up 1.2 percentage points year on year. This increase was a welcome development and shows it was recently more efficient because its expenses grew slower than its revenue. Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Sadly for Illumina, its EPS declined by 9.2% annually over the last five years while its revenue grew by 4.1%. This tells us the company became less profitable on a per-share basis as it expanded. We can take a deeper look into Illumina's earnings to better understand the drivers of its performance. As we mentioned earlier, Illumina's adjusted operating margin improved this quarter but declined by 2.1 percentage points over the last five years. Its share count also grew by 8.1%, meaning the company not only became less efficient with its operating expenses but also diluted its shareholders. In Q4, Illumina reported EPS at $0.86, up from $0.14 in the same quarter last year. Despite growing year on year, this print missed analysts' estimates. Over the next 12 months, Wall Street expects Illumina's full-year EPS of $4.07 to grow 9%. We enjoyed seeing Illumina exceed analysts' organic revenue expectations this quarter, where it broke its three-quarter streak of organic revenue declines. We were also glad its full-year EPS guidance outperformed Wall Street's estimates. On the other hand, its full-year revenue guidance fell slightly short. Zooming out, we think this was a decent quarter featuring some areas of strength but also some blemishes. The areas below expectations seem to be driving the move, and the stock traded down 4.9% to $116.81 immediately following the results. Big picture, is Illumina a buy here and now? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Sign in to access your portfolio
